Elizabeth Crowley - Dec 8, 2021 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
Sr. VP &CPDO
Signature
/s/ Samuel Martin, attorney in fact for Elizabeth Crowley
Stock symbol
CLDX
Transactions as of
Dec 8, 2021
Transactions value $
-$123,934
Form type
4
Date filed
12/10/2021, 03:02 PM
Previous filing
Nov 3, 2021
Next filing
Jun 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $36.1K +4K +84.64% $9.02 8.73K Dec 8, 2021 Direct F1
transaction CLDX Common Stock Sale -$160K -4K -45.84% $40.00 4.73K Dec 8, 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -4K -20% $0.00 16K Dec 8, 2021 Common Stock 4K $9.02 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 300,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.
F2 The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 15, 2021.
F3 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.